Prelude Therapeutics Incorporated
PRLD
Cena:
$ 4.27
-0.06 (-1.39%)
Valuace
70
Růst
60
Zdraví
75
Zprávy
Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
PRELUDE THERAPEUTICS RECEIVES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION (IND) FOR PRT12396, A MUTANT-SELECTIVE JAK2V617F INHIBITOR
03-02-2026
WILMINGTON, DEL., FEB. 03, 2026 (GLOBE NEWSWIRE) -- PRELUDE THERAPEUTICS INCORPORATED (NASDAQ: PRLD)...
Více zde
PRELUDE THERAPEUTICS PRESENTS DATA AT THE 2025 ASH ANNUAL MEETING FROM ITS MYELOPROLIFERATIVE NEOPLASM (MPN) PROGRAMS
06-12-2025
FIRST DISCLOSURE OF PRT12396, A JAK2V617F-SELECTIVE JH2 INHIBITOR DEMONSTRATES DISEASE MODIFYING POT...
Více zde
PRLD INVESTORS HAVE OPPORTUNITY TO JOIN PRELUDE THERAPEUTICS INCORPORATED FRAUD INVESTIGATION WITH THE SCHALL LAW FIRM
26-11-2025
LOS ANGELES, NOV. 26, 2025 (GLOBE NEWSWIRE) -- THE SCHALL LAW FIRM, A NATIONAL SHAREHOLDER RIGHTS LI...
Více zde
INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF PRELUDE THERAPEUTICS INCORPORATED - PRLD
20-11-2025
NEW YORK , NOV. 20, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTO...
Více zde
PRLD INVESTORS HAVE OPPORTUNITY TO JOIN PRELUDE THERAPEUTICS INCORPORATED FRAUD INVESTIGATION WITH THE SCHALL LAW FIRM
19-11-2025
LOS ANGELES, NOV. 19, 2025 (GLOBE NEWSWIRE) -- THE SCHALL LAW FIRM, A NATIONAL SHAREHOLDER RIGHTS LI...
Více zde
PRELUDE THERAPEUTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
12-11-2025
LEAD CANDIDATE FROM MUTANT SELECTIVE JAK2V617F JH2 INHIBITOR PROGRAM ADVANCING WITH IND FILING EXPEC...
Více zde
PRLD INVESTORS HAVE OPPORTUNITY TO JOIN PRELUDE THERAPEUTICS INCORPORATED FRAUD INVESTIGATION WITH THE SCHALL LAW FIRM
11-11-2025
LOS ANGELES--(BUSINESS WIRE)---- $PRLD--PRLD INVESTORS HAVE OPPORTUNITY TO JOIN PRELUDE THERAPEUTICS...
Více zde
PRELUDE THERAPEUTICS ANNOUNCES STRATEGIC BUSINESS UPDATE
04-11-2025
PRELUDE TO PRIORITIZE DEVELOPMENT OF MUTANT SELECTIVE JAK2V617F JH2 INHIBITOR AND KAT6A SELECTIVE DE...
Více zde
PRELUDE THERAPEUTICS ANNOUNCES EXCLUSIVE OPTION AGREEMENT WITH INCYTE TO ADVANCE MUTANT SELECTIVE JAK2V617F JH2 INHIBITORS
04-11-2025
INCYTE SECURES AN EXCLUSIVE OPTION TO ACQUIRE PRELUDE'S MUTANT SELECTIVE JAK2V617F JH2 INHIBITOR PRO...
Více zde
PRELUDE THERAPEUTICS ANNOUNCES PUBLICATION OF ABSTRACTS FOR PRESENTATION AT THE AMERICAN SOCIETY OF HEMATOLOGY 67TH ANNUAL MEETING
03-11-2025
WILMINGTON, DEL., NOV. 03, 2025 (GLOBE NEWSWIRE) -- PRELUDE THERAPEUTICS INCORPORATED (NASDAQ: PRLD)...
Více zde
PRELUDE THERAPEUTICS ANNOUNCES APPOINTMENT OF KATINA DORTON, J.D., MBA TO ITS BOARD OF DIRECTORS
17-10-2025
WILMINGTON, DEL., OCT. 17, 2025 (GLOBE NEWSWIRE) -- PRELUDE THERAPEUTICS INCORPORATED (NASDAQ: PRLD)...
Více zde
PRELUDE THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
14-08-2025
PRT7732, ONCE DAILY ORAL SMARCA2 DEGRADER, CURRENTLY ENROLLING AT THE SEVENTH DOSING COHORT (125 MG)...
Více zde
PRELUDE THERAPEUTICS TO PARTICIPATE IN UPCOMING HEALTHCARE CONFERENCES
02-06-2025
WILMINGTON, DEL., JUNE 02, 2025 (GLOBE NEWSWIRE) -- PRELUDE THERAPEUTICS INCORPORATED (PRELUDE) (NAS...
Více zde
PRELUDE THERAPEUTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
06-05-2025
PRT3789 MONOTHERAPY AND COMBINATION WITH DOCETAXEL ESCALATION ENROLLMENT IS COMPLETE AND THE COMPANY...
Více zde
PRELUDE THERAPEUTICS TO PARTICIPATE IN CITIZENS LIFE SCIENCES CONFERENCE
01-05-2025
WILMINGTON, DEL., MAY 01, 2025 (GLOBE NEWSWIRE) -- PRELUDE THERAPEUTICS INCORPORATED (PRELUDE) (NASD...
Více zde
PRELUDE ANNOUNCES PRESENTATIONS AT 2025 AACR ANNUAL MEETING
25-04-2025
PRECLINICAL DATA ELUCIDATING THE MECHANISM OF ACTION OF PRT3789, PRELUDE'S FIRST-IN-CLASS, HIGHLY SE...
Více zde
PRELUDE THERAPEUTICS REPORTS FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES PROGRAM OUTLOOK FOR 2025
10-03-2025
PRT3789 HAS DEMONSTRATED CLINICAL PROOF-OF-CONCEPT THAT SELECTIVELY DEGRADING SMARCA2 IS GENERALLY S...
Více zde
PRELUDE THERAPEUTICS TO PARTICIPATE IN BARCLAYS 27TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
05-03-2025
WILMINGTON, DEL., MARCH 05, 2025 (GLOBE NEWSWIRE) -- PRELUDE THERAPEUTICS INCORPORATED (PRELUDE) (NA...
Více zde
PRELUDE THERAPEUTICS PRESENTS PRELIMINARY RESULTS OF PHASE 1 DOSE-ESCALATION STUDY OF PRT2527 AS MONOTHERAPY AND IN COMBINATION WITH ZANUBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY LYMPHOID MALIGNANCIES
11-12-2024
• PRT2527 DEMONSTRATED ACTIVITY ACROSS A RANGE OF RELAPSED/REFRACTORY LYMPHOID MALIGNANCIES, INCLU...
Více zde
PRELUDE THERAPEUTICS TO PARTICIPATE IN CITIZENS JMP SECURITIES HEMATOLOGY AND ONCOLOGY SUMMIT
27-11-2024
WILMINGTON, DEL., NOV. 27, 2024 (GLOBE NEWSWIRE) -- PRELUDE THERAPEUTICS INCORPORATED (PRELUDE) (NAS...
Více zde
PRELUDE THERAPEUTICS PRESENTS NEW DATA FROM SMARCA DEGRADER PORTFOLIO AT THE 36TH EORTC-NCI-AACR SYMPOSIUM
24-10-2024
– INTERIM DATA FROM ONGOING TRIAL OF PRT3789 SHOWED ADDITIONAL CLINICAL ACTIVITY AT HIGHER DOSES I...
Více zde
PRELUDE THERAPEUTICS ANNOUNCES PUBLICATION OF ABSTRACTS FOR PRESENTATION AT THE 36TH EORTC-NCI-AACR SYMPOSIUM
09-10-2024
PRT3789, A NOVEL, HIGHLY-SELECTIVE SMARCA2 DEGRADER IN PATIENTS WITH ADVANCED SOLID TUMORS WITH A SM...
Více zde
PRELUDE THERAPEUTICS' SMARCA2 DEGRADER PRT3789 DEMONSTRATED PROMISING INITIAL CLINICAL ACTIVITY AND SAFETY PROFILE IN PHASE 1 TRIAL
13-09-2024
- ENCOURAGING SIGNS OF ANTI-TUMOR ACTIVITY INCLUDING OBJECTIVE RESPONSES OBSERVED IN PATIENTS WITH...
Více zde
PRELUDE THERAPEUTICS ANNOUNCES PUBLICATION OF ABSTRACT FOR PRESENTATION AT THE EUROPEAN SOCIETY OF MEDICAL ONCOLOGY (ESMO) CONGRESS 2024
09-09-2024
PRT3789, A NOVEL, HIGHLY-SELECTIVE SMARCA2 DEGRADER IN PATIENTS WITH ADVANCED SOLID TUMORS WITH A SM...
Více zde
PRELUDE THERAPEUTICS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
12-08-2024
INTERIM PHASE 1 DATA FOR ITS FIRST-IN-CLASS, HIGHLY SELECTIVE IV SMARCA2 DEGRADER, PRT3789, SELECTED...
Více zde
PRELUDE THERAPEUTICS ANNOUNCES CLINICAL COLLABORATION WITH MERCK TO EVALUATE PRT3789 IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) IN PATIENTS WITH SMARCA4-MUTATED CANCERS
09-07-2024
COMBINING A FIRST-IN-CLASS, HIGHLY SELECTIVE SMARCA2 DEGRADER WITH AN ANTI-PD-1 THERAPY MAY POTENTIA...
Více zde
PRELUDE THERAPEUTICS TO PARTICIPATE IN UPCOMING HEALTHCARE CONFERENCES
03-06-2024
WILMINGTON, DEL., JUNE 03, 2024 (GLOBE NEWSWIRE) -- PRELUDE THERAPEUTICS INCORPORATED (NASDAQ: PRLD)...
Více zde
PRELUDE THERAPEUTICS TO PARTICIPATE IN CITIZENS JMP LIFE SCIENCES CONFERENCE
09-05-2024
WILMINGTON, DEL., MAY 09, 2024 (GLOBE NEWSWIRE) -- PRELUDE THERAPEUTICS INCORPORATED (PRELUDE) (NASD...
Více zde
PRELUDE THERAPEUTICS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
07-05-2024
FIRST-IN-CLASS IV SMARCA2 DEGRADER, PRT3789 AND POTENTIALLY BEST-IN-CLASS CDK9 INHIBITOR, PRT2527 RE...
Více zde
PRELUDE HIGHLIGHTS CONTINUED STRENGTH OF DISCOVERY ENGINE AT 2024 AACR ANNUAL MEETING
09-04-2024
HIGHLY SELECTIVE ORAL SMARCA2 DEGRADER, PRT7732, SHOWS ROBUST ANTI-TUMOR ACTIVITY IN VIVO AS MONOTHE...
Více zde
| Datum | Typ | Otevřít EDGAR | Stáhnout dokument |
|---|---|---|---|
| 2026-02-03 00:00:00 | 8-K |  | Stáhnout |
| 2026-01-09 00:00:00 | 8-K | | Stáhnout |
| 2025-11-12 00:00:00 | 8-K | | Stáhnout |
| 2025-11-12 00:00:00 | 10-Q | | Stáhnout |
| 2025-11-04 00:00:00 | 8-K | | Stáhnout |
| 2025-10-17 01:00:00 | 8-K | | Stáhnout |
| 2025-10-17 00:00:00 | 8-K | | Stáhnout |
| 2025-09-19 01:00:00 | 8-K | | Stáhnout |
| 2025-09-19 00:00:00 | 8-K | | Stáhnout |
| 2025-08-14 01:00:00 | 8-K | | Stáhnout |
| 2025-08-14 01:00:00 | 10-Q | | Stáhnout |
| 2025-08-14 00:00:00 | 8-K | | Stáhnout |
| 2025-08-14 00:00:00 | 10-Q | | Stáhnout |
| 2025-06-13 01:00:00 | 8-K | | Stáhnout |
| 2025-06-13 00:00:00 | 8-K | | Stáhnout |
| 2025-05-06 01:00:00 | 8-K | | Stáhnout |
| 2025-05-06 01:00:00 | 10-Q | | Stáhnout |
| 2025-05-06 00:00:00 | 8-K | | Stáhnout |
| 2025-05-06 00:00:00 | 10-Q | | Stáhnout |
| 2025-04-25 01:00:00 | 8-K | | Stáhnout |
| 2025-04-25 00:00:00 | 8-K | | Stáhnout |
| 2025-03-28 00:00:00 | 8-K | | Stáhnout |
| 2025-03-27 23:00:00 | 8-K | | Stáhnout |
| 2025-03-10 00:00:00 | 8-K | | Stáhnout |
| 2025-03-10 00:00:00 | 10-K | | Stáhnout |
| 2025-03-09 23:00:00 | 8-K | | Stáhnout |
| 2025-03-09 23:00:00 | 10-K | | Stáhnout |
| 2025-02-05 00:00:00 | 8-K | | Stáhnout |
| 2025-02-04 23:00:00 | 8-K | | Stáhnout |
| 2024-12-11 00:00:00 | 8-K | | Stáhnout |
| 2024-12-10 23:00:00 | 8-K | | Stáhnout |
| 2024-11-06 00:00:00 | 8-K | | Stáhnout |
| 2024-11-06 00:00:00 | 10-Q | | Stáhnout |
| 2024-11-05 23:00:00 | 8-K | | Stáhnout |
| 2024-11-05 23:00:00 | 10-Q | | Stáhnout |
| 2024-10-24 01:00:00 | 8-K | | Stáhnout |
| 2024-10-24 00:00:00 | 8-K | | Stáhnout |
| 2024-09-13 01:00:00 | 8-K | | Stáhnout |
| 2024-09-13 00:00:00 | 8-K | | Stáhnout |
| 2024-09-09 01:00:00 | 8-K | | Stáhnout |
| 2024-09-09 00:00:00 | 8-K | | Stáhnout |
| 2024-08-12 01:00:00 | 8-K | | Stáhnout |
| 2024-08-12 01:00:00 | 10-Q | | Stáhnout |
| 2024-08-12 00:00:00 | 8-K | | Stáhnout |
| 2024-08-12 00:00:00 | 10-Q | | Stáhnout |
| 2024-06-18 01:00:00 | 8-K | | Stáhnout |
| 2024-06-18 00:00:00 | 8-K | | Stáhnout |
| 2024-06-12 01:00:00 | 8-K | | Stáhnout |
| 2024-06-12 00:00:00 | 8-K | | Stáhnout |
| 2024-05-07 01:00:00 | 8-K | | Stáhnout |
| 2024-05-07 01:00:00 | 10-Q | | Stáhnout |
| 2024-05-07 00:00:00 | 8-K | | Stáhnout |
| 2024-05-07 00:00:00 | 10-Q | | Stáhnout |
| 2024-04-10 01:00:00 | 8-K | | Stáhnout |
| 2024-04-10 00:00:00 | 8-K | | Stáhnout |
| 2024-02-15 00:00:00 | 8-K | | Stáhnout |
| 2024-02-15 00:00:00 | 10-K | | Stáhnout |
| 2024-02-14 23:00:00 | 8-K | | Stáhnout |
| 2024-02-14 23:00:00 | 10-K | | Stáhnout |
| 2023-12-11 00:00:00 | 8-K | | Stáhnout |
| 2023-12-10 23:00:00 | 8-K | | Stáhnout |
| 2023-11-01 00:00:00 | 8-K | | Stáhnout |
| 2023-11-01 00:00:00 | 10-Q | | Stáhnout |
| 2023-10-31 23:00:00 | 8-K | | Stáhnout |
| 2023-10-31 23:00:00 | 10-Q | | Stáhnout |
| 2023-08-03 01:00:00 | 8-K | | Stáhnout |
| 2023-08-03 01:00:00 | 10-Q | | Stáhnout |
| 2023-08-03 00:00:00 | 8-K | | Stáhnout |
| 2023-08-03 00:00:00 | 10-Q | | Stáhnout |
| 2023-06-21 01:00:00 | 8-K | | Stáhnout |
| 2023-06-21 00:00:00 | 8-K | | Stáhnout |
| 2023-06-01 01:00:00 | 8-K | | Stáhnout |
| 2023-06-01 00:00:00 | 8-K | | Stáhnout |
| 2023-05-19 01:00:00 | 8-K | | Stáhnout |
| 2023-05-19 00:00:00 | 8-K | | Stáhnout |
| 2023-05-17 01:00:00 | 8-K | | Stáhnout |
| 2023-05-17 00:00:00 | 8-K | | Stáhnout |
| 2023-05-08 01:00:00 | 8-K | | Stáhnout |
| 2023-05-08 01:00:00 | 10-Q | | Stáhnout |
| 2023-05-08 00:00:00 | 8-K | | Stáhnout |
| 2023-05-08 00:00:00 | 10-Q | | Stáhnout |
| 2023-03-15 00:00:00 | 8-K | | Stáhnout |
| 2023-03-15 00:00:00 | 10-K | | Stáhnout |
| 2023-03-14 23:00:00 | 8-K | | Stáhnout |
| 2023-03-14 23:00:00 | 10-K | | Stáhnout |
| 2023-02-14 00:00:00 | 8-K | | Stáhnout |
| 2023-02-13 23:00:00 | 8-K | | Stáhnout |
| 2023-01-23 00:00:00 | 8-K | | Stáhnout |
| 2023-01-22 23:00:00 | 8-K | | Stáhnout |
| 2023-01-09 00:00:00 | 8-K | | Stáhnout |
| 2023-01-08 23:00:00 | 8-K | | Stáhnout |
| 2022-11-14 00:00:00 | 8-K | | Stáhnout |
| 2022-11-14 00:00:00 | 10-Q | | Stáhnout |
| 2022-11-13 23:00:00 | 8-K | | Stáhnout |
| 2022-11-13 23:00:00 | 10-Q | | Stáhnout |
| 2022-08-09 01:00:00 | 8-K | | Stáhnout |
| 2022-08-09 01:00:00 | 10-Q | | Stáhnout |
| 2022-08-09 00:00:00 | 8-K | | Stáhnout |
| 2022-08-09 00:00:00 | 10-Q | | Stáhnout |
| 2022-06-21 01:00:00 | 8-K | | Stáhnout |
| 2022-06-21 00:00:00 | 8-K | | Stáhnout |
| 2022-05-10 01:00:00 | 8-K | | Stáhnout |
| 2022-05-10 01:00:00 | 10-Q | | Stáhnout |
| 2022-05-10 00:00:00 | 8-K | | Stáhnout |
| 2022-05-10 00:00:00 | 10-Q | | Stáhnout |
| 2022-04-08 01:00:00 | 8-K | | Stáhnout |
| 2022-04-08 00:00:00 | 8-K | | Stáhnout |
| 2022-03-17 00:00:00 | 10-K | | Stáhnout |
| 2022-03-16 23:00:00 | 10-K | | Stáhnout |
| 2022-03-16 00:00:00 | 8-K | | Stáhnout |
| 2022-03-15 23:00:00 | 8-K | | Stáhnout |
| 2022-03-09 00:00:00 | 8-K | | Stáhnout |
| 2022-03-08 23:00:00 | 8-K | | Stáhnout |
| 2022-02-16 00:00:00 | 8-K | | Stáhnout |
| 2022-02-15 23:00:00 | 8-K | | Stáhnout |
| 2022-01-10 00:00:00 | 8-K | | Stáhnout |
| 2022-01-09 23:00:00 | 8-K | | Stáhnout |
| 2021-12-03 00:00:00 | 8-K | | Stáhnout |
| 2021-12-02 23:00:00 | 8-K | | Stáhnout |
| 2021-11-12 00:00:00 | 8-K | | Stáhnout |
| 2021-11-12 00:00:00 | 10-Q | | Stáhnout |
| 2021-11-11 23:00:00 | 8-K | | Stáhnout |
| 2021-11-11 23:00:00 | 10-Q | | Stáhnout |
| 2021-09-17 01:00:00 | 8-K | | Stáhnout |
| 2021-09-17 00:00:00 | 8-K | | Stáhnout |
| 2021-08-12 01:00:00 | 8-K | | Stáhnout |
| 2021-08-12 01:00:00 | 10-Q | | Stáhnout |
| 2021-08-12 00:00:00 | 8-K | | Stáhnout |
| 2021-08-12 00:00:00 | 10-Q | | Stáhnout |
| 2021-07-19 01:00:00 | 8-K | | Stáhnout |
| 2021-07-19 00:00:00 | 8-K | | Stáhnout |
| 2021-06-22 01:00:00 | 8-K | | Stáhnout |
| 2021-06-22 00:00:00 | 8-K | | Stáhnout |
| 2021-05-12 01:00:00 | 8-K | | Stáhnout |
| 2021-05-12 00:00:00 | 8-K | | Stáhnout |
| 2021-05-11 01:00:00 | 8-K | | Stáhnout |
| 2021-05-11 01:00:00 | 10-Q | | Stáhnout |
| 2021-05-11 00:00:00 | 8-K | | Stáhnout |
| 2021-05-11 00:00:00 | 10-Q | | Stáhnout |
| 2021-03-17 00:00:00 | 8-K | | Stáhnout |
| 2021-03-16 23:00:00 | 8-K | | Stáhnout |
| 2021-03-16 00:00:00 | 8-K | | Stáhnout |
| 2021-03-16 00:00:00 | 10-K | | Stáhnout |
| 2021-03-15 23:00:00 | 8-K | | Stáhnout |
| 2021-03-15 23:00:00 | 10-K | | Stáhnout |
| 2021-03-08 00:00:00 | 8-K | | Stáhnout |
| 2021-03-07 23:00:00 | 8-K | | Stáhnout |
| 2021-01-28 00:00:00 | 8-K | | Stáhnout |
| 2021-01-27 23:00:00 | 8-K | | Stáhnout |
| 2021-01-04 00:00:00 | 8-K | | Stáhnout |
| 2021-01-03 23:00:00 | 8-K | | Stáhnout |
| 2020-11-10 00:00:00 | 8-K | | Stáhnout |
| 2020-11-10 00:00:00 | 10-Q | | Stáhnout |
| 2020-11-09 23:00:00 | 8-K | | Stáhnout |
| 2020-11-09 23:00:00 | 10-Q | | Stáhnout |
| 2020-11-04 00:00:00 | 8-K | | Stáhnout |
| 2020-11-03 23:00:00 | 8-K | | Stáhnout |
